22157.jpg
The Worldwide Cardiovascular Drugs Industry is Expected to Reach $96+ Billion by 2026
26 janv. 2022 06h43 HE | Research and Markets
Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Cardiovascular Drugs Market (2021-2026) by Drug Type, Disease Indications, Distribution Channel, Geography, Competitive Analysis and the Impact...
22157.jpg
Global Heparin Market (2021 to 2027) - Featuring Pfizer, Sanofi and LEO Pharma Among Others
26 janv. 2022 06h38 HE | Research and Markets
Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Heparin Market By Type, By Application, By Route of Administration, By End Use, By Regional Outlook, COVID-19 Impact Analysis Report and...
Aronora Announces Clinical Data to Be Presented at the 63rd American Society of Hematology Annual Meeting
06 déc. 2021 08h00 HE | Aronora, Inc
PORTLAND, Ore., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing innovative therapies for hematologic diseases, today announced that clinical data...
logo long.jpg
Acute Ischemic Stroke (AIS) Market to Surpass US$ 11,185.3 Million by 2028, Says Coherent Market Insights (CMI)
10 nov. 2021 09h00 HE | CMI
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global acute ischemic stroke (AIS) market is estimated to be valued at US$ 8,517.0 Million in 2021 and is...
22157.jpg
Insights on the Anticoagulants Global Market to 2025 - Rising Prevalence of Cardiovascular Disease is Driving Growth
22 sept. 2021 08h28 HE | Research and Markets
Dublin, Sept. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Anticoagulants Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 sept. 2021 08h30 HE | ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
09 août 2021 08h00 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
22157.jpg
Europe Anticoagulant Reversal Drug Market Report 2021-2027: Market Opportunities with Increasing Research Activities on Anticoagulant Reversal Drugs
20 juil. 2021 04h03 HE | Research and Markets
Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Europe Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product; End User" report has been added to...
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
13 juil. 2021 08h00 HE | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment...
22157.jpg
Worldwide Anticoagulants Industry to 2026 - Featuring Aspen Holdings, Bayer and Pfizer Among Others
07 juil. 2021 04h33 HE | Research and Markets
Dublin, July 07, 2021 (GLOBE NEWSWIRE) -- The "Global Anticoagulants Market (2021-2026) by Drug Class, Route of Administration, Geography and the Impact of COVID-19 with Ansoff Analysis" report has...